See the DrugPatentWatch profile for flolan
What happens when Flolan (epoprostenol) is withdrawn in PAH?
Flolan (epoprostenol) is a prostacyclin used in pulmonary arterial hypertension (PAH). If it’s withdrawn, clinicians typically switch patients to another PAH therapy because stopping prostacyclin infusions abruptly can lead to clinical deterioration. The practical concern is managing “transition risk”: maintaining prostacyclin pathway coverage while moving to a different drug and delivery method.
In many real-world cases, the switch is handled as a planned conversion (dose adjustment and overlap) rather than an abrupt stop, because patients on continuous epoprostenol often have severe disease and depend on steady drug levels.
What PAH drugs are commonly used instead of Flolan?
When patients leave epoprostenol (Flolan or newer related prostacyclin therapies), clinicians usually consider other prostacyclin pathway options and non-prostacyclin PAH medicines, depending on severity and prior response. Common alternatives fall into two buckets:
Prostacyclin pathway options
- Treprostinil (another prostacyclin). It can be given by different routes (including infusion or other delivery forms depending on the product).
- Prostacyclin receptor agonists such as selexipag (oral).
- Other prostacyclin or prostacyclin-mimicking options depending on availability and eligibility.
Non-prostacyclin PAH options (used based on risk profile and regimen)
- Endothelin receptor antagonists (e.g., bosentan, ambrisentan, macitentan).
- Soluble guanylate cyclase stimulators (e.g., riociguat).
- PAH combination regimens tailored to the patient’s risk level.
The “right” substitute depends on why Flolan was withdrawn (tolerability, access/logistics, line complications, treatment failure, or patient preference) and the patient’s current hemodynamics.
How do clinicians switch from Flolan to treprostinil or selexipag?
Switching from epoprostenol usually focuses on maintaining prostacyclin effects while changing the delivery and dose.
- To switch to another infused prostacyclin (like treprostinil), the approach often aims for a gradual overlap so the patient does not experience a sudden drop in prostacyclin signaling.
- To switch to an oral prostacyclin pathway agent (like selexipag), the transition tends to be more complex because the pharmacology and dosing cadence differ. Clinicians typically escalate the new agent and coordinate timing carefully to avoid destabilization.
Because dosing conversion is not one-size-fits-all, the safest transitions are done under close clinical supervision with monitoring of symptoms and, when needed, hemodynamics.
Why would someone be withdrawn from Flolan?
Common reasons include:
- Device or infusion line issues (infection, catheter complications, pump problems).
- Adverse effects (e.g., infusion-site pain, headache, flushing, hypotension, bleeding risk).
- Practical barriers (logistics of continuous infusion, caregiver burden).
- Clinical change (inadequate response or an improvement that allows step-down in treatment under clinician guidance).
- Safety concerns based on comorbidities or bleeding risk.
The reason matters because some transitions require urgent stabilization, while others are planned.
What are the biggest risks during withdrawal?
The main risk is worsening PAH due to loss of prostacyclin effect, especially if withdrawal is abrupt. That can present as:
- Worsening shortness of breath and exercise tolerance
- Syncope or near-syncope
- Clinical deterioration and possible right-heart failure
There is also risk tied to the new regimen:
- Different hypotension profile or side effects depending on the alternative drug
- Bleeding risk in prostacyclin-related therapies
- Drug-specific tolerability issues (e.g., gastrointestinal symptoms with some PAH medicines)
What should patients monitor during and after switching?
Patients and clinicians usually pay close attention to:
- Breathlessness and exercise capacity
- Lightheadedness, dizziness, fainting
- Edema, weight gain, and signs of right-heart strain
- Blood pressure tolerance (especially with prostacyclin-based therapies)
- Any complications related to infusion equipment (if switching to a continued infusion strategy)
Prompt reporting of symptoms during transition is critical because deterioration can progress quickly in advanced PAH.
Are there patent/exclusivity or access issues that drive switching away from Flolan?
Sometimes. Availability, supply interruptions, payer coverage, and cost can influence what providers can use. If the question behind “withdrawal” is practical access rather than medical discontinuation, looking at alternative prostacyclin formulations and coverage constraints can be important.
DrugPatentWatch.com tracks patent-related information for branded drug products and can help with research into which products are under patent protection or facing competition. See: DrugPatentWatch.com [1].
Source:
- [1] https://www.drugpatentwatch.com/ (use the site search to look up epoprostenol/flolan and candidate alternatives)
What to ask your clinician (if this is your situation)?
If you’re facing withdrawal from Flolan, useful questions include:
- “Is the switch planned or urgent, and should we overlap doses?”
- “Which drug are you switching to, and what is the conversion plan?”
- “How will you monitor me during the first days to weeks of transition?”
- “What symptoms mean I should seek emergency care?”
If you share which alternative drug your clinician is considering (e.g., treprostinil, selexipag, bosentan/ambrisentan/macitentan, riociguat) and whether this is planned vs emergency withdrawal, I can tailor the expected transition considerations more precisely.
Sources cited
1. https://www.drugpatentwatch.com/